GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » e-Therapeutics PLC (LSE:ETX) » Definitions » Additional Paid-In Capital

e-Therapeutics (LSE:ETX) Additional Paid-In Capital : £112.63 Mil(As of Jul. 2023)


View and export this data going back to 2007. Start your Free Trial

What is e-Therapeutics Additional Paid-In Capital?


e-Therapeutics's quarterly additional paid-in capital increased from Jul. 2022 (£99.25 Mil) to Jan. 2023 (£112.61 Mil) and increased from Jan. 2023 (£112.61 Mil) to Jul. 2023 (£112.63 Mil).

e-Therapeutics's annual additional paid-in capital increased from Jan. 2021 (£77.67 Mil) to Jan. 2022 (£99.24 Mil) and increased from Jan. 2022 (£99.24 Mil) to Jan. 2023 (£112.61 Mil).

e-Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for e-Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

e-Therapeutics Additional Paid-In Capital Chart

e-Therapeutics Annual Data
Trend Jan14 Jan15 Jan16 Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 65.17 65.18 77.67 99.24 112.61

e-Therapeutics Semi-Annual Data
Jan14 Jul14 Jan15 Jul15 Jan16 Jul16 Jan17 Jul17 Jan18 Jul18 Jan19 Jul19 Jan20 Jul20 Jan21 Jul21 Jan22 Jul22 Jan23 Jul23
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 99.23 99.24 99.25 112.61 112.63

e-Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

e-Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of e-Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

e-Therapeutics (LSE:ETX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » e-Therapeutics PLC (LSE:ETX) » Definitions » Additional Paid-In Capital
Comparable Companies
LSE:POLB LSE:SAR LSE:AREC LSE:OBD LSE:TRX LSE:DEST LSE:SBTX LSE:HEMO LSE:OPTI LSE:C4XD OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XKRX:068270 BNTX ALNY
Traded in Other Exchanges
ETXPF:USA 3AQ:Germany
Address
4 Kingdom Street, Paddington, London, GBR, W2 6BD
Website
https://www.etherapeutics.co.uk
e-Therapeutics PLC is a drug discovery company. Its ambition is to transform the drug discovery process, leveraging its computational network biology platform (drug discovery) to find novel targets to address mechanisms underpinning complex disease. l company activities are carried out in the UK.

e-Therapeutics (LSE:ETX) Headlines

From GuruFocus

Eaton Vance Municipal Income 2028 Term Trust Announces Telephonic Annual Meeting Of Shareholders On November 12, 2021

By PRNewswire PRNewswire • 11-02-2021